What is HC Wainwright’s Forecast for ZNTL Q1 Earnings?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at HC Wainwright dropped their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.52) per share for the quarter, down from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.11) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.61) EPS, FY2028 earnings at ($1.96) EPS and FY2029 earnings at ($0.99) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter.

A number of other research analysts have also recently commented on ZNTL. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research note on Thursday, January 30th. Wedbush restated a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday. Finally, UBS Group decreased their price target on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL opened at $1.81 on Monday. The company has a 50-day simple moving average of $2.04 and a two-hundred day simple moving average of $2.85. The firm has a market capitalization of $129.98 million, a PE ratio of -0.73 and a beta of 1.75. Zentalis Pharmaceuticals has a one year low of $1.61 and a one year high of $16.27.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 14.1% during the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after purchasing an additional 7,058 shares during the last quarter. Wells Fargo & Company MN raised its stake in Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock valued at $105,000 after buying an additional 7,305 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Paloma Partners Management Co bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at $37,000. Finally, Corton Capital Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth $32,000.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Ingmar Bruns acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the completion of the transaction, the insider now directly owns 36,629 shares of the company’s stock, valued at approximately $83,514.12. This represents a 120.27 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the completion of the acquisition, the director now directly owns 149,551 shares in the company, valued at $257,227.72. This represents a 67.00 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.